Clinical Trial Update: An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of investigational immunotherapy BMS-986277 alone and with nivolumab in epithelial cancers has been terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• BMS-986277
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-12-19